Beecham Group Plc

Eric A Watts

Francis D King

Michael S Hadley

Gordon Wootton

Christine Summers

Roger T Martin

Francis E Blaney

Peptides comprising, in sequence, units selected from the amino acid residues 17 to 24 of VIP, and consisting at least of the amino acid residues 18 to 23, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid; having anti-ulcer activity, a process for their preparation and their use as pharmaceuticals.

Peptides containing the 18 to 23 residues of vasoactive intestinal

Compounds of formula (I) and pharmaceutically acceptable salts thereof:

N-('-B-hydroxyethylpiperid-4-yl esters and amides

Compounds of formula (i) and pharmaceutically acceptable salts thereof: ##STR1## wherein: m and n are independently 1 or 2 and p is 0, 1 or 2 such that m+n+p.gtoreq.3;

N-heterocyclic derivatives of benzamides and their use in treating

Peptides comprising, in sequence, units selected from the amino acid residues 11 to 23 of vasoactive intestinal peptide (VIP) and consisting at least of the amino acid residues 15 to 20, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid, or a pharmaceutically acceptable salt thereof; having pharmacological activity, a process for their preparation and their use as pharmaceuticals.

VIP type peptides

Compounds of formula (I): ##STR1## wherein: one of X and Y is CO and the other is NH;

Certain 5-N-mono- or disubstituted sulfamoyl benzamides having use in

Compounds of formula (I), pharmaceutically acceptable salts, quaternary derivatives and N-oxides thereof, and pharmaceutically acceptable solvates of any of the foregoing: ##STR1## wherein p is 1 to 3;

Compounds

Pharmaceutical compositions comprising compounds of formula (I) or pharmaceutically acceptable salts and/or N-oxides and/or solvates thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy or C.sub.1-6 alkylthio group; and

Nortropane and granatane type compounds useful in treating psychosis

Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: n, p and q independently are 0 to 2;

Pharmaceutically active aza-bicyclo benzamide derivatives

Compounds of the formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is C.sub.1-6 alkyl;

Aza-bicyclo-benzamide derivatives and pharmaceutical compositions and

A compound of the formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group;

Benzamide derivatives

Compounds of the formula (I), and their pharmaceutically acceptable salts: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group;

Treating gastro-intestinal disorders and emesis with n-(heterocyclic

Orally and parenterally administrable compositions for the treatment of hypertension, the active hypotensive agent of which is an aminochromanol or pharmaceutically acceptable acid addition salt thereof. The preparation of the active agent is described.

4-Amino-6-nitro derivatives of 2H-3,4-dihydrobenzo[b]pyrans

Anti-hypertensive derivatives of trans-3-hydroxy-4-amino-chroman, their preparation from amines and chroman epoxide derivatives, and pharmaceutical compositions containing such anti-hypertensive derivatives for reducing blood pressure in mammals, including humans.

Chroman derivatives

Derivatives of trans-3-hydroxy-4-amino-chroman and pharmaceutical compositions containing such derivatives are useful for effecting vasodilation in mammals, including humans.

Compounds of the formula ##STR1## wherein R.sub.3 is hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkoxyl of 1 to 6 carbon atoms, alkenyloxyl of 2 to 6 carbon atoms, alkylthio of 1 to 6 carbon atoms, hydroxyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino of 1 to 6 carbon atoms, nitro, trifluoromethyl, acylamino of 2 to 7 carbon atoms, alkoxysulphonylamino of 1 to 6 carbon atoms, carboxyl, nitrile, AOR.sub.4, ASR.sub.7, ASO.sub.2 R.sub.7, ANHR.sub.7, ANR.sub.7 COR.sub.8, ANR.sub.7 SO.sub.2 R.sub.8 or ANR.sub.7 CO.sub.2 R.sub.8, wherein A is alkylene of 1 to 4 carbon atoms, R.sub.7 is alkyl of 1 to 4 carbon atoms and R.sub.8 is alkyl of 1 to 4 carbon atoms;

Growing community of inventors

Harlow, United Kingdom

Eric A Watts